Variations of the endothelial nitric oxide synthase (eNOS) gene have been associated with hypertensive disorders of pregnancy. We examined whether eNOS polymorphisms affect the therapeutic responses of women with gestational hypertension (GH) or preeclampsia (PE). We studied 304 hypertensive pregnant women (152 GH and 152 PE), who were stratified according to clinical and laboratorial parameters of therapeutic responsiveness. We compared the frequencies of three eNOS genetic polymorphisms (T-786C, Glu298Asp and b/a intron 4) in responsive and nonresponsive PE and GH patients. We found no significant differences in genotype or allele distributions when responsive and nonresponsive groups were compared (both PE or GH; all P40.05). However, the eNOS haplotype distribution differed in PE (but not in GH)-responsive and -nonresponsive groups (P ¼ 0.0003). The 'C-Glu-a' and 'T-Asp-a' hapotypes were associated with responsiveness and nonresponsiveness to therapy, respectively (both Po0.001), thus suggesting that eNOS haplotypes affect the responsiveness to antihypertensive therapy in PE.
Introduction
Hypertension is the most common medical disorder in pregnancy and affects approximately 10% of all pregnancies. 1 Among the hypertensive disorders of pregnancy, preeclampsia (PE) is associated with various maternal and fetal complications, including renal failure, liver failure, cerebral edema, prematurity and death. 2, 3 At present, it is widely accepted that the increases in blood pressure observed in PE result from poor placental perfusion. 4 Although antihypertensive drugs do not reverse the pathophysiological alterations of PE, they allow maintenance of gestation and increase the gestational age of delivery, thus decreasing adverse fetal and maternal outcomes. 5 Moreover, these medications may prevent cardiovascular and acute cerebrovascular events associated with rapid increases in blood pressure levels, at least in some pregnant women. 6 In this regard, the guidelines for antihypertensive treatment of pregnant disorders (NHBPEP, National High Blood Pressure Education Program Working Group Report on High Blood Pressure in Pregnancy) include therapeutic recommendations based on specific diagnosis (mild-to-moderate hypertension, severe hypertension and PE) and on the targeted blood pressure level. 1 Typically, the therapy includes methyldopa, nifedipine, hydralazine and labetalol. 5 The clinical effects produced by many antihypertensive drugs, such as calcium channel blockers and some b-blockers, involve increased nitric oxide (NO) bioavailability. 7, 8 This small molecule has a major effect in the regulation of vascular tone, 9 and increased NO production has been described in normal pregnancy. 10, 11 Conversely, reduced NO formation has been reported in both gestational hypertension (GH) and PE, thus suggesting a potential role of NO deficiency in the pathogenesis of hypertensive disorders of pregnancy. [12] [13] [14] In addition, earlier studies have found significant associations between clinically relevant 15 genetic polymorphisms or haplotypes of the endothelial nitric oxide synthase (eNOS) gene and hypertensive disorders of pregnancy, 16 thus suggesting that genetic variations may predispose to these hypertensive conditions of pregnancy. However, no earlier study has examined the hypothesis that eNOS polymorphisms or haplotypes could affect the antihypertensive effects of drugs used to treat GH or PE.
In this study, our main goal was to compare the distribution of genetic variants of three clinically relevant eNOS polymorphisms in gestational hypertensive and preeclamptic pregnant women who are responsive to antihypertensive therapy, with the distribution of these variants in corresponding pregnant women who do not respond to these drugs. Table 1 summarizes the characteristics of 152 gestational hypertensive and 152 PE patients enrolled in this study. These pregnant women were classified into two groups (responsive and nonresponsive to antihypertensive therapy) on the basis of criteria described in the Materials and methods section.
Results
The responsive and nonresponsive groups of patients, either with GH or with PE, were matched by age, ethnicity, smoking, % primigravida and body mass index (Table 1 ; all P40.05). As expected in PE and GH patients, the nonresponsive group presented higher systolic and diastolic blood pressure levels than did their respective responsive groups (Table 1 ; both Po0.05). Although responsive and nonresponsive GH patients showed similar proteinuria and gestational age at delivery (Table 1 ; both P40.05), higher proteinuria, lower gestational age at delivery and lower newborn weights were found in nonresponsive PE patients than in responsive PE patients (Table 1 ; all Po0.05). Table 2 shows the results of a single-locus analysis. The distribution of genotypes for the three polymorphisms studied here showed no deviation from Hardy-Weinberg equilibrium (all P40.05). No significant differences were found in genotypes and allele distributions when responsive and nonresponsive groups of GH or PE patients were compared (Table 2 ; all P40.05).
We then carried out a further analysis, taking into consideration eNOS haplotype rather than single eNOS genotype distributions in responsive and nonresponsive groups. We found no significant differences in eNOS haplotype distribution when responsive and nonresponsive GH patients were compared (Table 3 ; P40.05). However, we found significant differences in the overall distribution of eNOS haplotypes when PE responsive and PE nonresponsive patients were compared (Table 4 ; P ¼ 0.0003). Specifically, although the 'C Glu a' haplotype was more frequent in the responsive PE group than in the nonresponsive PE group (36 versus 10%; P ¼ 0.0003; Odds ratio ¼ 3.65; (CI 95% ¼ 1.74-7.67; Table 4), the 'T Asp a' haplotype was less frequent in the responsive PE group than in the nonresponsive PE group (7 versus 22%; P ¼ 0.0007; Odds ratio 0.23 (CI 95% ¼ 0.09-0.58; Table 4 ). 
Discussion
The main finding of this study was that eNOS haplotypes 'C Glu a' and 'T Asp a' are associated with responsiveness and nonresponsiveness, respectively, to antihypertensive therapy in PE patients, but not in GH patients. To our knowledge, this is the first report on the possible association between eNOS haplotypes and antihypertensive therapy responsiveness. Interestingly, although the overall distribution of eNOS haplotype frequencies differed significantly when the group of responsive PE patients was compared with the group of nonresponsive PE patients, no significant associations were found when single-locus analysis was carried out. These findings are consistent with the suggestion that interactions of multiple genetic markers, and not individual markers, within haplotypes are major determinants of complex phenotypes such as disease susceptibility or response to drugs. [16] [17] [18] [19] [20] [21] We found no significant differences in the distribution of eNOS genotypes or haplotypes when patients with GH were stratified according to antihypertensive therapy responses. These findings are supported by earlier results showing that 19 In addition, the fact that eNOS haplotypes modify the responsiveness to antihypertensive therapy in PE patients but not in GH patients suggests that PE and GH may have a different genetic basis, at least in terms of responses to drug therapy.
NO is a major player in the regulation of vascular tone and in protecting target organs, 9, 22 and altered NO availability has been associated with eNOS genetic variations [23] [24] [25] and with hypertensive disorders of pregnancy. 16, 26 Although no earlier study has examined whether eNOS polymorphisms or haplotypes modify the effects of drugs used to treat GH or PE, a few studies showed that eNOS polymorphisms affect the responses to drugs that upregulate eNOS expression or increased NO release. [27] [28] [29] [30] [31] In this study, we found that eNOS polymorphisms do not affect responses to methyldopa, which was used in as an initial therapy for hypertensive disorders of pregnancy. Although there is no evidence that methyldopa produces antihypertensive effects by mechanisms involving increased NO production, it has been reported that several calcium channel blockers (including nifedipine) may improve endothelial function and restore NO bioavailability. 32, 33 In addition, hydralazine, which is widely used in the treatment of PE, enhanced cyclic guanosine 3 0 5 0 monophosphate concentrations in preeclamptic pregnant women, thus suggesting that this drug produces its effects by activating NO synthesis. 34 Therefore, it is possible that the drugs used to treat hypertensive disorders of pregnancy produce their effects by enhancing NO bioavailability, thus counteracting the impaired NO formation that has been reported in these hypertensive conditions. [12] [13] [14] Our findings reported here are consistent with this suggestion and also indicate that combinations of eNOS polymorphisms (haplotypes) affect the responsiveness to drugs used in the therapy of PE patients.
Nonresponsiveness to antihypertensive therapy is associated with the worst clinical outcomes, both in PE and in GH, and the use of antihypertensive drugs to treat these conditions may improve maternal and fetal outcomes, although there are controversial opinions with regard to these ideas. 35, 36 Interestingly, the eNOS haplotype ('C Glu a') that was found in association with responsiveness to antihypertensive therapy in PE patients is the same eNOS haplotype reported earlier in association with increased susceptibility to PE. It is possible that this particular eNOS haplotype leads to a lower NO availability in PE patients, which is improved by antihypertensive drugs. However, this hypothesis remains to be tested.
It should be made clear that the criteria that we used in this study to evaluate the lack of response to therapy may have affected our conclusions. Although there is no clear definition about how to precisely assess the severity of these hypertensive disorders of pregnancy, it is possible that responsiveness to therapy is affected by disease severity. Further studies are required to improve our understanding of these medical disorders of pregnancy.
In conclusion, our findings suggest that eNOS haplotypes affect responsiveness to antihypertensive therapy in PE patients. These findings are obscured when specific eNOS genotypes alone are considered, thus highlighting the importance of haplotypic structure to the genetic component of complex diseases and drug responses. 37 Although our study focused only on eNOS genetic variants, it would be interesting to examine whether other polymorphisms modulate the responsiveness to hypertensive disorders of pregnancy.
Materials and methods

Subjects
Approval for use of human subjects was obtained from the Institutional Review Board at the Faculty of Medicine of Ribeirao Preto, University of Sao Paulo, Brazil. All patients were enrolled in the Department of Obstetrics and Gynecology, University Hospital of the Faculty of Medicine of Ribeirao Preto. We studied 304 pregnant patients (152 with GH and 152 with PE). Hypertensive disorders were defined in accordance with the guidelines of the NHBPEP. 1 GH was defined as pregnancy-induced hypertension (X140 mm Hg systolic or X90 mm Hg diastolic on two or more measurements at least 6 h apart) without significant proteinuria (o0.3 g per 24 h) in a woman after 20 weeks of gestation, which returned to normal by 12 weeks postpartum. PE was defined as increased blood pressure (X140 mm Hg systolic or X90 mm Hg diastolic on two or more measurements at least 6 h apart) with significant proteinuria (X0.3 g per 24 h) in a woman after 20 weeks of gestation. No women with preexisting hypertension, with or without superimposed PE, were included in this study.
At the time of clinic attendance, maternal venous blood samples were collected and genomic DNA was extracted from the cellular component of 1 ml of whole blood by a salting-out method and was stored at 20 1C until analyzed.
Antihypertensive treatment and drug response evaluation
The patients included in this study were monitored closely for signs and symptoms of PE, with careful fetal surveillance and laboratory tests at least twice weekly. Responsiveness to therapy was based on the evaluation of clinical and laboratory parameters (see below) in response to the administration of antihypertensive drugs. The initial antihypertensive drug of choice was methyldopa (1000-1500 mg per day), followed by nifedipine (40-60 mg dia -1 ) and/or hydralazine (5-30 mg dia -1 ), which were added in case of lack of significant responses to methyldopa. The following clinical laboratory outcomes were considered as reflecting a lack of response to therapy: 
Genotype determination
Three clinically relevant eNOS gene polymorphisms were studied: the T-786C polymorphism in the 5'-flanking region of the eNOS gene, the variable number of tandem repeats (27 bp-repeat) polymorphism in intron 4 and the Glu298Asp polymorphism in exon 7. Genotypes for the T-786C and Glu298Asp polymorphisms were determined by the Taqman Allele Discrimination assay and by real-time PCR on a Chromo 4 Detector (Bio-Rad Laboratories, USA). Genotypes for the variable number of tandem repeats polymorphism in intron 4, however, were determined by PCR and fragment separation by electrophoresis in 8% polyacrylamide gels as described earlier.
15,38
Statistical analysis
The clinical characteristics of responsive groups of GH or PE patients were compared with those of respective nonresponsive groups of patients using Student's unpaired t-test. The categorical variables were compared between groups by w 2 -tests. The distribution of genotypes for each polymorphism was assessed for deviation from the Hardy-Weinberg equilibrium, and differences in genotype frequency and allele frequency between groups were assessed using w 2 -tests. A value of Po0.05 was considered as statistically significant.
The estimating haplotype (EH) software program (http:// www.genemapping.cn/eh.htm; accessed on April 15, 2009) was used to estimate the haplotype frequencies in each group. EH is a linkage utility program to test and estimate linkage disequilibrium between different markers or between a disease locus and markers. On the basis of sample data, haplotype frequencies are estimated with (H1) and without (H0) allelic association. The EH program also provides log likelihood, w 2 and the number of degrees of freedom under hypotheses H0 and H1, thus allowing the best choice between H0 and H1.
To identify which specific haplotypes are associated with therapy responsiveness, differences in haplotype frequency were further tested using a contingency table. The minimum level of statistical significance was corrected for the number of comparisons made. Therefore, we considered a probability value of Po0.05 per number of haplotypes (Po0.05/8 ¼ 0.0063) to be significant.
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